Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables - Net: 2021-2024

Historic Receivables - Net for Apellis Pharmaceuticals (APLS) over the last 4 years, with Dec 2024 value amounting to $264.9 million.

  • Apellis Pharmaceuticals' Receivables - Net rose 23.84% to $345.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.5 million, marking a year-over-year increase of 23.84%. This contributed to the annual value of $264.9 million for FY2024, which is 28.33% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Receivables - Net of $264.9 million as of FY2024, which was up 28.33% from $206.4 million recorded in FY2023.
  • Apellis Pharmaceuticals' Receivables - Net's 5-year high stood at $264.9 million during FY2024, with a 5-year trough of $7.7 million in FY2022.
  • For the 3-year period, Apellis Pharmaceuticals' Receivables - Net averaged around $159.7 million, with its median value being $206.4 million (2023).
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Receivables - Net decreased by 23.52% in 2022, and later surged by 2,571.70% in 2023.
  • Apellis Pharmaceuticals' Receivables - Net (Yearly) stood at $10.1 million in 2021, then declined by 23.52% to $7.7 million in 2022, then surged by 2,571.70% to $206.4 million in 2023, then rose by 28.33% to $264.9 million in 2024.